Respiratory Failure (Adult)

Overview

Respiratory failure is the inability of the respiratory system to maintain adequate gas exchange, resulting in hypoxemia (PaO₂ less than 60 mmHg on room air) and/or hypercapnia (PaCO₂ > 50 mmHg with pH less than 7.35). [1] It represents a final common pathway for numerous pulmonary and extrapulmonary disorders and accounts for 10-40% of ICU admissions. [2]

Respiratory failure is classified into Type 1 (hypoxemic), Type 2 (hypercapnic), Type 3 (perioperative atelectasis), and Type 4 (shock-related hypoperfusion). The distinction between Type 1 and Type 2 has critical implications for oxygen therapy, ventilation strategy, and prognosis. [3]

The alveolar-arterial (A-a) gradient is the key physiological calculation that distinguishes pulmonary causes (elevated A-a gradient) from extrapulmonary causes such as hypoventilation (normal A-a gradient). [4]

---

Epidemiology

Risk Factors

For Acute Respiratory Failure:

• Pneumonia (most common precipitant)
• COPD exacerbation
• Congestive heart failure
• Pulmonary embolism
• Aspiration
• Sepsis
• Trauma
• Neuromuscular weakness

For ARDS:

• Sepsis (most common, 40% of cases) [5]
• Pneumonia
• Aspiration of gastric contents
• Major trauma
• Massive transfusion
• Pancreatitis
• Drug overdose

---

Classification

Type 1: Hypoxemic Respiratory Failure

Definition: PaO₂ less than 60 mmHg on room air with normal or low PaCO₂ (less than 45 mmHg)

Mechanisms:

1. Ventilation-perfusion (V/Q) mismatch (most common)

   • Blood flows past poorly ventilated alveoli
   • Responds well to supplemental oxygen
   • Examples: Pneumonia, COPD, asthma, PE

2. Intrapulmonary shunt

   • Blood bypasses ventilated alveoli entirely
   • Poor response to supplemental oxygen
   • Examples: ARDS, pulmonary edema, consolidation, arteriovenous malformations

3. Diffusion impairment

   • Thickened alveolar-capillary membrane
   • Worsens with exercise
   • Examples: Interstitial lung disease, pulmonary fibrosis

4. Low inspired oxygen (FiO₂)

   • High altitude
   • Enclosed space fires

Type 2: Hypercapnic Respiratory Failure

Definition: PaCO₂ > 50 mmHg (with or without hypoxemia)

Acute: pH less than 7.35 (uncompensated) Chronic: pH ≥7.35 (compensated with elevated bicarbonate) Acute-on-chronic: pH 7.25-7.35 (partially compensated)

Mechanisms (organized by anatomical level):

Type 3: Perioperative Respiratory Failure

• Atelectasis following abdominal or thoracic surgery
• Reduced functional residual capacity
• Diaphragm dysfunction
• Pain limiting deep breathing

Type 4: Shock-Related Respiratory Failure

• Hypoperfusion → tissue hypoxia
• Occurs despite adequate oxygen delivery
• Cardiogenic, septic, or hypovolemic shock
• Lactic acidosis present

Mixed Respiratory Failure

Many patients have features of both Type 1 and Type 2:

• COPD exacerbation (V/Q mismatch + hypoventilation)
• Severe pneumonia with fatigue
• Neuromuscular disease with aspiration pneumonia

---

Pathophysiology

The Alveolar Gas Equation

The alveolar-arterial (A-a) gradient is calculated to determine whether hypoxemia is due to a pulmonary or extrapulmonary cause:

PAO₂ = (FiO₂ × [Patm - PH₂O]) - (PaCO₂ / RQ)

At sea level on room air:
PAO₂ = (0.21 × [760 - 47]) - (PaCO₂ / 0.8)
PAO₂ ≈ 150 - (PaCO₂ / 0.8)

A-a gradient = PAO₂ - PaO₂

Normal A-a gradient: 5-15 mmHg (increases with age)

• Estimate: Normal A-a gradient ≈ (Age / 4) + 4

Interpretation:

• Normal A-a gradient: Extrapulmonary cause (hypoventilation, low FiO₂)
• Elevated A-a gradient: Pulmonary cause (V/Q mismatch, shunt, diffusion defect)

Response to Supplemental Oxygen

Compensatory Mechanisms

1. Increased minute ventilation

   • Tachypnea (most sensitive early sign)
   • Increased tidal volume
   • Limited by work of breathing

2. Cardiovascular compensation

   • Tachycardia
   • Increased cardiac output
   • Limited by cardiac reserve

3. Hypoxic pulmonary vasoconstriction

   • Diverts blood from poorly ventilated areas
   • Improves V/Q matching
   • May cause pulmonary hypertension

4. Eventual decompensation

   • Diaphragmatic fatigue (paradoxical breathing)
   • Respiratory acidosis
   • Cardiovascular collapse

---

Clinical Presentation

Symptoms

Early Hypoxemia:

• Dyspnea (most common)
• Tachypnea (RR > 24/min)
• Anxiety, restlessness
• Tachycardia

Severe Hypoxemia:

• Confusion, altered mental status
• Cyanosis (central: SpO₂ less than 85%)
• Bradycardia (pre-arrest sign)
• Loss of consciousness

Hypercapnia (CO₂ retention):

• Headache (cerebral vasodilation)
• Drowsiness, somnolence
• Confusion, CO₂ narcosis
• Asterixis ("CO₂ flap")
• Flushed, warm skin
• Bounding pulses
• Papilledema (chronic severe)

Signs of Impending Respiratory Arrest

Physical Examination

Respiratory Findings:

Cardiovascular Findings:

• Jugular venous distension: Right heart failure, PE, tension pneumothorax
• Peripheral edema: Heart failure
• Hypotension: Shock, severe PE, tension pneumothorax

Neurological Findings:

• Asterixis: Hypercapnia
• Confusion: Hypoxemia or hypercapnia
• Focal deficits: Stroke (cause of Type 2 RF)

---

Red Flags

Life-Threatening Causes (Must Not Miss)

Warning Signs for Intubation

Clinical criteria (intubation is a CLINICAL decision, not based on numbers alone):

• Unable to protect airway (GCS ≤8, poor gag)
• Respiratory arrest or agonal breathing
• Severe work of breathing with impending fatigue
• Refractory hypoxemia (SpO₂ less than 85-90% despite maximal support)
• Progressive hypercapnia with acidosis (pH less than 7.25) despite NIV
• Hemodynamic instability
• Need for deep sedation, transport, or procedure

---

Differential Diagnosis

Approach by Type

Type 1 (Hypoxemic) - Common Causes:

Type 2 (Hypercapnic) - Common Causes:

---

Diagnostic Approach

Arterial Blood Gas (ABG) Interpretation

Step-by-step approach:

1. Assess oxygenation: PaO₂ less than 60 mmHg = respiratory failure
2. Assess pH: less than 7.35 acidemia, > 7.45 alkalemia
3. Determine primary disturbance: Which moved pH (↑PaCO₂ or ↓HCO₃)?
4. Assess compensation: Has the opposite parameter responded?
5. Calculate A-a gradient: Elevated = pulmonary cause

Key ABG Values:

P/F Ratio (PaO₂/FiO₂ Ratio)

Critical metric for assessing severity of hypoxemic respiratory failure:

Important: P/F ratio must be calculated with PEEP ≥5 cm H₂O for ARDS diagnosis per Berlin criteria. [5]

Imaging

Chest X-Ray (first-line for all patients):

CT Chest:

• CT pulmonary angiography (CTPA): PE suspected (use Wells criteria/PERC rule first)
• High-resolution CT: Interstitial lung disease
• Better characterization of infiltrates, masses, effusions
• Not routinely needed in ED

Laboratory Studies

Additional Testing

• ECG: Arrhythmias, ischemia, RV strain (S1Q3T3 in PE)
• Echocardiography: LV function (CHF), RV strain (PE), valvular disease
• Bronchoscopy: Aspiration, diffuse alveolar hemorrhage, infection (BAL)
• Pulmonary function tests: Not in acute setting; for chronic Type 2 RF

---

Management Principles

Five Pillars of Respiratory Failure Management

1. Optimize oxygenation (SpO₂ 92-96%; 88-92% in COPD)
2. Support ventilation (correct hypercapnia if acidotic)
3. Treat underlying cause (antibiotics, diuretics, bronchodilators)
4. Minimize lung injury (lung-protective ventilation if intubated)
5. Supportive care (hemodynamics, nutrition, prophylaxis)

Oxygen Therapy Escalation

Oxygen Targets:

• General population: SpO₂ 92-96%
• COPD/chronic CO₂ retainers: SpO₂ 88-92% [11]
• Avoiding excessive oxygen reduces mortality in COPD exacerbations

High-Flow Nasal Cannula (HFNC)

Mechanism of action:

• Delivers heated, humidified oxygen up to 60 L/min
• Washes out nasopharyngeal dead space
• Provides low-level PEEP (2-5 cm H₂O)
• Reduces work of breathing

Evidence: The 2025 RENOVATE trial showed HFNC was noninferior to NIV for preventing intubation/death in most types of acute respiratory failure, including non-immunocompromised hypoxemia, ACPE, and hypoxemic COVID-19. However, the trial suggested possible inferiority in immunocompromised patients and COPD with respiratory acidosis (though sample sizes were small). [10]

Indications:

• Acute hypoxemic respiratory failure (alternative to NIV)
• Post-extubation respiratory support
• Palliative care (comfort)

Advantages over NIV:

• Better tolerated (no face mask)
• Can eat, drink, talk
• Less claustrophobia

Limitations:

• Cannot provide high levels of positive pressure
• Not suitable for severe hypercapnia with acidosis
• Immunocompromised patients may do better with NIV

---

Non-Invasive Positive Pressure Ventilation (NIPPV)

Evidence-Based Indications

Key Evidence:

• NIV reduces intubation rate by 65% and mortality by 55% in COPD exacerbations with respiratory acidosis (pH 7.25-7.35) [6]
• CPAP/BiPAP reduces intubation by 50% in acute cardiogenic pulmonary edema [7,13]
• Early NIV in immunocompromised patients may prevent intubation [14]

BiPAP Settings

Initial settings:

• IPAP (Inspiratory Positive Airway Pressure): Start 10-12 cm H₂O
  • Increase by 2 cm H₂O increments to improve ventilation (↓ PaCO₂)
  • Max usually 20-25 cm H₂O
• EPAP (Expiratory Positive Airway Pressure): Start 4-5 cm H₂O
  • Increase to improve oxygenation (↑ PaO₂)
  • Recruits alveoli, increases functional residual capacity
• FiO₂: Titrate to achieve SpO₂ target
• Respiratory rate backup: 12-16/min (ensures minimum ventilation)

Pressure support = IPAP - EPAP (aim for 8-12 cm H₂O initially)

CPAP vs BiPAP

Contraindications to NIV

NIV Failure - When to Intubate

Re-assess at 1-2 hours. Signs of failure:

• No improvement or worsening work of breathing
• Worsening or persistent acidosis (pH less than 7.25-7.30)
• Worsening hypoxemia (SpO₂ less than 85-88%)
• New or worsening altered mental status
• Hemodynamic instability
• Patient intolerance (agitation, mask removal)
• Copious secretions

Risk factors for NIV failure:

• APACHE II score > 29
• pH less than 7.25
• Pneumonia as cause
• Inability to coordinate with ventilator
• Excessive secretions

---

Endotracheal Intubation and Mechanical Ventilation

Intubation Indications

Absolute indications:

• Respiratory or cardiac arrest
• Severe hypoxemia refractory to NIV/HFNC (SpO₂ less than 85% on maximal support)
• Inability to protect airway (GCS ≤8, absent gag reflex)
• Massive hemoptysis or aspiration
• Airway obstruction

Relative indications (clinical judgment):

• Failure of NIV (see above)
• Progressive fatigue, impending respiratory arrest
• Severe acidosis (pH less than 7.20-7.25) despite NIV
• Hemodynamic instability requiring vasopressors
• Need for deep sedation (seizures, agitation)
• Need for transport or procedure

Rapid Sequence Intubation (RSI) Considerations

Pre-oxygenation:

• Goal: Denitrogenate lungs (5 minutes 100% O₂ or 8 vital capacity breaths)
• Use HFNC or NIV to extend safe apnea time
• Apneic oxygenation: Continue HFNC 15 L/min during laryngoscopy [15]

Induction agents:

Neuromuscular blocking agents:

• Succinylcholine 1.5 mg/kg (rapid onset, short duration)
• Rocuronium 1.2 mg/kg (alternative if succinylcholine contraindicated)

Post-intubation hypotension:

• Common due to ↓ sympathetic tone, ↑ intrathoracic pressure (especially in auto-PEEP)
• Have vasopressors ready (norepinephrine, push-dose epinephrine)
• Avoid excessive PEEP initially in obstructive disease

Initial Ventilator Settings

Mode: Assist-control (AC) or pressure control (PC)

Ideal Body Weight (IBW) calculation:

• Male: 50 kg + 2.3 kg per inch over 5 feet
• Female: 45.5 kg + 2.3 kg per inch over 5 feet

Lung-Protective Ventilation (ARDS)

The ARDSNet low tidal volume trial demonstrated a 9% absolute mortality reduction with lung-protective ventilation. [16]

Principles:

1. Low tidal volume: 6 mL/kg IBW (not actual body weight!)
2. Plateau pressure limit: less than 30 cm H₂O (prevents barotrauma)
3. Driving pressure: less than 15 cm H₂O (ΔP = Plateau pressure - PEEP)
4. Permissive hypercapnia: Allow PaCO₂ 50-60 mmHg, pH ≥7.20
5. PEEP titration: Use ARDSNet high PEEP table for moderate/severe ARDS
6. FiO₂ minimization: Wean FiO₂ less than 0.6 to reduce oxygen toxicity

Monitoring:

• Plateau pressure: Pause at end-inspiration, should be less than 30 cm H₂O
• Auto-PEEP: Pause at end-expiration (problematic in COPD/asthma)
• Driving pressure: Best predictor of mortality in ARDS

ARDS-Specific Therapies

For moderate-to-severe ARDS (P/F less than 150):

Prone positioning (PROSEVA trial, 2013): [17]

• 16 hours/day prone, less than 8 hours supine
• Reduces mortality from 32.8% to 16% (severe ARDS)
• Improves V/Q matching (better ventilation of dorsal lungs)

Conservative fluid management (FACTT trial): [19]

• Target CVP 4-6 mmHg or net negative fluid balance
• Use diuretics once hemodynamically stable
• Reduces days on ventilator, does not affect mortality

---

Specific Conditions

COPD Exacerbation with Respiratory Acidosis

Diagnosis: pH less than 7.35, PaCO₂ > 50 mmHg (acute-on-chronic if HCO₃⁻ > 30)

Management:

1. Controlled oxygen: Target SpO₂ 88-92% (avoid oxygen-induced hypercapnia) [11]
2. BiPAP: First-line ventilatory support (IPAP 12-15, EPAP 4-5) [6,12]
3. Bronchodilators: Nebulized albuterol 2.5-5 mg + ipratropium 0.5 mg q20min × 3, then q4-6h
4. Corticosteroids: Prednisone 40 mg PO daily × 5 days [21]
5. Antibiotics: If increased sputum purulence (amoxicillin-clavulanate or doxycycline)
6. Intubate if: pH less than 7.25 despite NIV, ↓ consciousness, hemodynamic instability

Avoid:

• Excessive oxygen (worsens hypercapnia via Haldane effect and V/Q mismatch)
• Sedatives (worsen hypoventilation)

Acute Cardiogenic Pulmonary Edema (ACPE)

Diagnosis: Dyspnea, orthopnea, bilateral crackles, elevated BNP, cardiomegaly, pulmonary edema on CXR

Management:

1. CPAP or BiPAP: Reduces intubation and mortality [7,13]
   • CPAP 5-10 cm H₂O OR BiPAP (IPAP 12-15, EPAP 5-8)
2. IV diuretics: Furosemide 40-80 mg IV (or 1-2× home dose)
3. Vasodilators (if hypertensive): Nitroglycerin 10-20 mcg/min IV, uptitrate
4. Treat underlying cause: MI (antiplatelet, anticoagulation), arrhythmia (rate control), hypertensive emergency
5. Avoid: Morphine (no benefit, may harm), excessive fluid removal (cardiogenic shock)

Severe Asthma Exacerbation

Diagnosis: Wheeze, accessory muscle use, peak flow less than 40% predicted

Management:

1. Continuous nebulized albuterol: 10-15 mg/hour
2. IV corticosteroids: Methylprednisolone 125 mg IV
3. Ipratropium: 0.5 mg nebulized q20min × 3
4. Magnesium sulfate: 2 g IV over 20 min (if severe, FEV₁ less than 40%)
5. Consider epinephrine: 0.3 mg IM (if imminent arrest)
6. Avoid NIV in severe asthma: Risk of barotrauma (pneumothorax, pneumomediastinum)
7. Intubate if: Silent chest, altered MS, exhaustion, pH less than 7.20

Post-intubation pitfalls:

• Auto-PEEP → hypotension (reduce rate, prolong expiratory time)
• Use ketamine for induction (bronchodilator)
• Low PEEP, low rate, prolonged expiratory time

Pneumonia with Respiratory Failure

Management:

1. Antibiotics within 1 hour: Ceftriaxone 1-2 g IV + azithromycin 500 mg IV (or doxycycline)
   • Add vancomycin if MRSA risk (recent hospitalization, IVDU, prior MRSA)
   • Add anti-pseudomonal coverage if risk factors (bronchiectasis, prior pseudomonas)
2. Oxygen/ventilatory support: Escalate as above
3. Sepsis management: Fluids, vasopressors if shock
4. Consider: Steroids if severe CAP (controversial, may add prednisone 50 mg × 7 days)

Intubation threshold: Lower in septic shock, high lactate, or rapidly progressive hypoxemia

---

Ventilator Weaning and Liberation

Readiness for Weaning

Prerequisites:

1. Underlying cause resolved or improving
2. Adequate oxygenation (P/F > 150-200, PEEP ≤5-8, FiO₂ ≤0.4-0.5)
3. Hemodynamic stability (no/minimal vasopressors)
4. Spontaneous breathing efforts
5. Alert, able to protect airway

Spontaneous Breathing Trial (SBT)

Method:

• T-piece or low-level pressure support (PS 5-7, PEEP 5) for 30-120 minutes
• Monitor for signs of failure

SBT failure criteria:

• SpO₂ less than 88-90%
• Respiratory rate > 35/min
• Tachycardia > 140 bpm or sustained ↑HR > 20%
• Systolic BP > 180 or less than 90 mmHg
• Anxiety, diaphoresis, altered mental status

Rapid Shallow Breathing Index (RSBI): RR / Tidal volume (L)

• RSBI less than 105: Likely successful extubation
• RSBI > 105: High risk of reintubation

Successful SBT → Extubate (if able to protect airway and manage secretions)

Post-Extubation Care

• High-flow nasal cannula: Reduces reintubation in high-risk patients [22]
• NIV: May prevent reintubation in COPD, high-risk patients
• Monitor closely first 24-48 hours (highest risk period for reintubation)

---

Disposition

ICU Admission Criteria

Absolute:

• Mechanical ventilation (intubated)
• NIV requirement (BiPAP/CPAP)
• Refractory hypoxemia (SpO₂ less than 90% on high-flow)
• Hemodynamic instability (vasopressor need)
• ARDS
• Status asthmaticus

Relative:

• High-flow nasal cannula > 40 L/min
• Frequent need for suctioning
• Altered mental status from respiratory failure
• High-risk cause (PE, sepsis, myasthenic crisis)

Step-Down/High-Dependency Unit

• Stable on low-dose NIV or HFNC
• Improving trajectory
• No vasopressor requirement
• Alert, cooperative

Discharge Criteria

• Returned to baseline oxygenation (or stable on home O₂)
• Underlying cause treated or plan in place
• Able to manage medications and follow-up
• Safe home environment
• Follow-up arranged

Follow-Up

---

Special Populations

COPD with Chronic Hypercapnia

Key principles:

• Baseline PaCO₂ is elevated (may be 50-60 mmHg at home)
• Target SpO₂ 88-92% (not 94-98%) to avoid oxygen-induced hypercapnia [11]
• Assess pH to determine acuity (chronic = pH normal despite ↑PaCO₂)
• BiPAP highly effective for acute-on-chronic exacerbations
• Avoid excessive oxygen (worsens hypercapnia)

Mechanisms of oxygen-induced hypercapnia:

1. Haldane effect (O₂ displaces CO₂ from hemoglobin)
2. Worsened V/Q mismatch (loss of hypoxic vasoconstriction)
3. Hypoventilation (↓ hypoxic drive in subset of patients)

Neuromuscular Disease

Examples: Myasthenia gravis, Guillain-Barré, ALS, muscular dystrophy

Key features:

• Weak cough → aspiration risk
• Shallow breathing without dyspnea (reduced respiratory drive)
• Normal lung exam (extrapulmonary cause)

Monitoring:

• Vital capacity (VC): Intubate if less than 15-20 mL/kg or rapidly declining
• Negative inspiratory force (NIF): Intubate if < -20 to -30 cm H₂O
• Frequent ABG monitoring (may not appear dyspneic despite severe hypercapnia)

NIV: May be effective for chronic support (ALS, Duchenne) but requires intact bulbar function

Obesity Hypoventilation Syndrome (OHS)

Definition: BMI > 30, daytime hypercapnia (PaCO₂ > 45 mmHg), sleep-disordered breathing

Pathophysiology:

• Increased work of breathing (chest wall restriction)
• Reduced lung compliance and functional residual capacity
• Obstructive sleep apnea (90% have OSA)

Management:

• BiPAP (effective for acute and chronic management)
• Weight loss
• Treat OSA
• Higher PEEP requirements (8-10 cm H₂O)

Pregnancy

Physiological changes:

• Baseline PaCO₂ is lower (30-32 mmHg due to progesterone-driven hyperventilation)
• Interpret ABG in context: PaCO₂ 40 mmHg in pregnancy = relative hypercapnia
• Functional residual capacity reduced (gravid uterus)
• Oxygen consumption increased

Management principles:

• Maternal oxygenation is priority for fetal well-being
• Target SpO₂ ≥95%
• Left lateral decubitus position (reduces aortocaval compression)
• Early involvement of obstetrics and neonatology

Elderly and Frail Patients

Considerations:

• Higher mortality from respiratory failure
• Frailty impacts goals of care discussions
• Higher risk of delirium with NIV/sedation
• Consider advance directives, code status early
• Functional decline post-ICU common (post-intensive care syndrome)

---

Complications of Mechanical Ventilation

Ventilator-Induced Lung Injury (VILI)

Mechanisms:

• Barotrauma: High airway pressures → pneumothorax, pneumomediastinum
• Volutrauma: Overdistention → alveolar damage (more important than pressure)
• Atelectrauma: Cyclical opening/closing of alveoli → shear stress
• Biotrauma: Inflammatory mediator release → multi-organ failure

Prevention:

• Low tidal volume (6 mL/kg IBW)
• Plateau pressure less than 30 cm H₂O
• Driving pressure less than 15 cm H₂O
• Appropriate PEEP (avoid atelectasis and overdistention)

Ventilator-Associated Pneumonia (VAP)

Definition: Pneumonia developing > 48 hours after intubation

Prevention:

• Head of bed elevation 30-45°
• Daily sedation interruption and SBT assessment
• Oral care with chlorhexidine
• Avoid reintubation

Diagnosis: New infiltrate + fever + purulent sputum + leukocytosis

Treatment: Broad-spectrum antibiotics (cover Pseudomonas, MRSA)

Other Complications

• Hypotension post-intubation: ↓ sympathetic tone, ↑ intrathoracic pressure
• Auto-PEEP: Air trapping in COPD/asthma → hypotension, barotrauma
• Oxygen toxicity: FiO₂ > 0.6 for prolonged periods → lung injury
• ICU delirium: Sedation, sleep deprivation → delirium
• ICU-acquired weakness: Prolonged immobility, NMB, steroids

---

Key Clinical Pearls

Diagnostic Pearls

1. ABG defines the type: Hypoxemic (Type 1), hypercapnic (Type 2), or mixed
2. A-a gradient distinguishes pulmonary from extrapulmonary causes: Normal A-a = hypoventilation
3. P/F ratio less than 200 = ARDS: Must have bilateral infiltrates + known risk factor
4. Acute vs chronic hypercapnia: pH tells you (acidotic = acute, normal = chronic)
5. BNP helps differentiate CHF from ARDS: BNP > 500 suggests cardiac cause [8]
6. Tachypnea is the earliest sign: Slowing respiratory rate may indicate fatigue (ominous)

Treatment Pearls

1. Intubation is a clinical decision: Don't wait for "perfect" ABG numbers
2. NIV prevents intubation in COPD and CHF: Strong evidence, NNT 4-5 [6,7,12,13]
3. HFNC is noninferior to NIV in most types of ARF: Better tolerated [10]
4. Low tidal volume (6 mL/kg IBW) saves lives in ARDS: ARDSNet trial [16]
5. Prone positioning reduces mortality in severe ARDS: 50% relative reduction (P/F less than 150) [17]
6. Target SpO₂ 88-92% in COPD: Avoid oxygen-induced hypercapnia [11]
7. Plateau pressure less than 30 cm H₂O prevents VILI: Check on all ventilated patients
8. BiPAP in COPD has NNT of 4-5: One of the most effective ED interventions [6]

Disposition Pearls

1. All intubated patients = ICU: No exceptions
2. NIV usually requires ICU or step-down: Rarely appropriate for floor
3. ARDS survivors need comprehensive follow-up: Physical, cognitive, psychological
4. Home oxygen needs reassessment: Often temporary for acute illness
5. First episode of respiratory failure warrants pulmonary referral: Investigate underlying cause

---

Common Exam Questions and Model Answers

Q1: "What are the mechanisms of hypoxemia?"

Model Answer: "There are five mechanisms of hypoxemia. The most common is V/Q mismatch, where blood flows past poorly ventilated alveoli, seen in pneumonia and COPD - this responds well to supplemental oxygen. Shunt is when blood bypasses ventilated alveoli entirely, as in ARDS and pulmonary edema, and responds poorly to oxygen. Diffusion impairment occurs with thickened alveolar-capillary membranes in interstitial lung disease. Hypoventilation causes hypoxemia with a normal A-a gradient, as in opioid overdose. Finally, low inspired oxygen occurs at high altitude. These are distinguished by the A-a gradient and response to supplemental oxygen."

Q2: "How would you manage a COPD patient with respiratory acidosis?"

Model Answer: "This patient has acute-on-chronic Type 2 respiratory failure. My priorities are: First, controlled oxygen therapy targeting SpO₂ 88-92% to avoid worsening hypercapnia. Second, BiPAP as first-line ventilatory support - there is strong evidence it reduces intubation and mortality with an NNT of 4-5. I would start with IPAP 12-15 and EPAP 4-5. Third, medical management with nebulized bronchodilators, corticosteroids for 5 days, and antibiotics if increased sputum purulence. I would repeat ABG in 1-2 hours - if pH remains less than 7.25 despite BiPAP or the patient develops altered consciousness or hemodynamic instability, I would proceed to intubation."

Q3: "What are the Berlin criteria for ARDS?"

Model Answer: "The Berlin criteria define ARDS as: Timing - within one week of a known clinical insult; Imaging - bilateral opacities on chest X-ray not fully explained by effusions or collapse; Origin - respiratory failure not fully explained by cardiac failure or fluid overload, requiring echo to exclude; and Oxygenation - P/F ratio with PEEP ≥5: mild ARDS is 200-300, moderate is 100-200, and severe is less than 100. These categories predict mortality of approximately 27%, 32%, and 45% respectively."

Q4: "How would you ventilate a patient with severe ARDS?"

Model Answer: "I would use lung-protective ventilation based on the ARDSNet protocol. This means tidal volume of 6 mL/kg ideal body weight, not actual weight, maintaining plateau pressure below 30 cm H₂O and driving pressure below 15. I would use adequate PEEP per the ARDSNet PEEP/FiO₂ table and accept permissive hypercapnia with pH down to 7.20. For severe ARDS with P/F ratio less than 150, I would implement prone positioning for 16 hours daily, which reduces mortality by 50% based on the PROSEVA trial. I would also use a conservative fluid strategy once hemodynamically stable."

---

References

1. Vincent JL, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-2329. doi:10.1001/jama.2009.1754

2. Halpern SD, et al. Critical care medicine in the United States 2000-2005: an analysis of bed numbers, occupancy rates, payer mix, and costs. Crit Care Med. 2010;38(1):65-71. doi:10.1097/CCM.0b013e3181b090d0

3. Roussos C, Koutsoukou A. Respiratory failure. Eur Respir J Suppl. 2003;47:3s-14s. doi:10.1183/09031936.03.00038503

4. Kanber GJ, et al. The alveolar-arterial oxygen gradient in young and elderly men during air and oxygen breathing. Am Rev Respir Dis. 1968;97(3):376-381.

5. ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526-2533. doi:10.1001/jama.2012.5669

6. Rochwerg B, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50(2):1602426. doi:10.1183/13993003.02426-2016

7. Weng CL, et al. Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema. Ann Intern Med. 2010;152(9):590-600. doi:10.7326/0003-4819-152-9-201005040-00009

8. Maisel AS, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. doi:10.1056/NEJMoa020233

9. Frat JP, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185-2196. doi:10.1056/NEJMoa1503326

10. Maia IS, et al; RENOVATE Investigators. High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial. JAMA. 2025;333(10):875-890. doi:10.1001/jama.2024.26244

11. O'Driscoll BR, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017;72(Suppl 1):ii1-ii90. doi:10.1136/thoraxjnl-2016-209729

12. Osadnik CR, et al. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;7(7):CD004104. doi:10.1002/14651858.CD004104.pub4

13. Vital FMR, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema. Cochrane Database Syst Rev. 2013;2013(5):CD005351. doi:10.1002/14651858.CD005351.pub3

14. Hilbert G, et al. Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. N Engl J Med. 2001;344(17):1481-1487. doi:10.1056/NEJM200104263441703

15. Weingart SD, Levitan RM. Preoxygenation and prevention of desaturation during emergency airway management. Ann Emerg Med. 2012;59(3):165-175. doi:10.1016/j.annemergmed.2011.10.002

16. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308. doi:10.1056/NEJM200005043421801

17. Guérin C, et al; PROSEVA Study Group. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168. doi:10.1056/NEJMoa1214103

18. Papazian L, et al; ACURASYS Study Investigators. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107-1116. doi:10.1056/NEJMoa1005372

19. Wiedemann HP, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354(24):2564-2575. doi:10.1056/NEJMoa062200

20. Combes A, et al; EOLIA Trial Group. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965-1975. doi:10.1056/NEJMoa1800385

21. Walters JAE, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;2014(9):CD001288. doi:10.1002/14651858.CD001288.pub4

22. Hernández G, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. JAMA. 2016;315(13):1354-1361. doi:10.1001/jama.2016.2711

23. Stefan MS, et al. Comparative effectiveness of noninvasive and invasive ventilation in critically ill patients with acute exacerbation of chronic obstructive pulmonary disease. Crit Care Med. 2015;43(7):1386-1394. doi:10.1097/CCM.0000000000000945

24. Fan E, et al. An Official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine Clinical Practice Guideline: Mechanical Ventilation in Adult Patients with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017;195(9):1253-1263. doi:10.1164/rccm.201703-0548ST

25. Barbas CSV, et al. Clinical practice parameters for mechanical ventilation. J Bras Pneumol. 2014;40(5):458-486. doi:10.1590/S1806-37132014000500003

26. Brochard L, et al. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit Care Med. 2017;195(4):438-442. doi:10.1164/rccm.201605-1081CP

---

Clinical Scenarios and Case-Based Learning

Case 1: COPD Exacerbation with Respiratory Acidosis

Presentation: A 68-year-old man with severe COPD presents with 3 days of worsening dyspnea and increased sputum production. He is using accessory muscles, RR 32/min, SpO₂ 84% on room air, HR 110 bpm, BP 145/85 mmHg. He is alert but appears fatigued.

Initial ABG (on room air):

• pH 7.28
• PaCO₂ 68 mmHg
• PaO₂ 52 mmHg
• HCO₃⁻ 31 mEq/L
• SpO₂ 84%

Interpretation: Acute-on-chronic Type 2 respiratory failure (partially compensated respiratory acidosis with hypoxemia)

Initial Management:

1. Controlled oxygen: Nasal cannula 2 L/min → SpO₂ improves to 90% (target 88-92%)
2. BiPAP: IPAP 12, EPAP 5, FiO₂ 0.28
3. Nebulized bronchodilators: Albuterol 2.5 mg + ipratropium 0.5 mg
4. Prednisone 40 mg PO (or methylprednisolone 125 mg IV)
5. Antibiotics: Doxycycline 100 mg PO BID (increased purulent sputum)

Repeat ABG after 2 hours on BiPAP:

• pH 7.34
• PaCO₂ 58 mmHg
• PaO₂ 68 mmHg
• HCO₃⁻ 30 mEq/L
• SpO₂ 92%

Outcome: Improved pH to acceptable range (> 7.30), continue BiPAP and medical management. Admit to ICU/step-down for monitoring. Patient improved over 48 hours and was weaned off BiPAP successfully.

Teaching Points:

• BiPAP has NNT of 4-5 for preventing intubation in COPD with acidosis
• Target SpO₂ 88-92% to avoid oxygen-induced hypercapnia
• pH is more important than absolute PaCO₂ (patient's baseline may be 55-60 mmHg)
• Repeat ABG at 1-2 hours to assess response

---

Case 2: Severe ARDS from Pneumonia

Presentation: A 45-year-old woman with influenza pneumonia deteriorates on hospital day 2. She is now requiring 15 L non-rebreather mask with persistent SpO₂ 88%, RR 35/min, appears exhausted. CXR shows bilateral infiltrates.

ABG (on 15 L NRB, FiO₂ ~0.8):

• pH 7.46
• PaCO₂ 32 mmHg
• PaO₂ 62 mmHg
• HCO₃⁻ 24 mEq/L

Calculate P/F Ratio: 62 / 0.8 = 77.5 → Severe ARDS (P/F less than 100)

Decision: Patient meets intubation criteria (refractory hypoxemia, severe work of breathing, P/F less than 100)

Intubation Approach:

1. Pre-oxygenation: Continue NRB, apply HFNC 60 L/min during pre-oxygenation
2. Induction: Etomidate 20 mg IV (hemodynamically stable)
3. Paralysis: Rocuronium 100 mg IV
4. Apneic oxygenation: Continue HFNC 15 L/min during laryngoscopy
5. Successful intubation, 7.5 mm ETT

Initial Ventilator Settings (Patient height 165 cm, IBW = 56 kg):

• Mode: Assist-control (volume control)
• Tidal volume: 6 mL/kg × 56 kg = 336 mL (set 340 mL)
• Respiratory rate: 18/min (for target minute ventilation)
• FiO₂: 1.0 initially
• PEEP: 10 cm H₂O (per ARDSNet high PEEP table for FiO₂ 1.0)
• I:E ratio: 1:2

Post-intubation ABG (30 minutes later):

• pH 7.38
• PaCO₂ 46 mmHg
• PaO₂ 88 mmHg
• Plateau pressure: 28 cm H₂O (acceptable, less than 30)
• Driving pressure: 28 - 10 = 18 cm H₂O (target less than 15, may need adjustment)

Adjustments:

• Wean FiO₂ to 0.7 (SpO₂ 92%)
• Continue PEEP 10 per ARDSNet table
• Consider reducing Vt to 320 mL to lower driving pressure

Day 2: P/F ratio remains less than 150 despite optimization

• Initiate prone positioning: 16 hours prone, 8 hours supine
• Continue lung-protective ventilation
• Conservative fluid management (target CVP less than 6 mmHg, negative balance)

Outcome: Patient improved over 7 days, successfully weaned and extubated on day 10.

Teaching Points:

• Always calculate IBW, not actual weight (common error!)
• P/F ratio less than 100 = severe ARDS with ~45% mortality
• Prone positioning for P/F less than 150 reduces mortality by 50%
• Plateau pressure and driving pressure are critical safety metrics

---

Case 3: Acute Cardiogenic Pulmonary Edema

Presentation: A 72-year-old man with history of MI and heart failure presents with acute dyspnea at rest, orthopnea, bilateral crackles. BP 180/100 mmHg, HR 115 bpm (irregular), RR 32/min, SpO₂ 86% on room air. JVD present, S3 gallop heard.

ECG: Atrial fibrillation with rapid ventricular response (rate 120 bpm)

CXR: Cardiomegaly, bilateral infiltrates, cephalization, Kerley B lines

ABG (on 6 L nasal cannula):

• pH 7.48
• PaCO₂ 32 mmHg
• PaO₂ 56 mmHg
• HCO₃⁻ 24 mEq/L

BNP: 1850 pg/mL (markedly elevated, supports cardiac cause)

Interpretation: Type 1 respiratory failure from acute cardiogenic pulmonary edema with respiratory alkalosis (hyperventilation from hypoxemia)

Management:

1. CPAP 10 cm H₂O or BiPAP (IPAP 15, EPAP 8)
   • Improves oxygenation, reduces preload and afterload
   • Strong evidence for reducing intubation
2. IV furosemide 80 mg (double home dose of 40 mg)
3. Nitroglycerin infusion 10 mcg/min, uptitrate (BP permits)
4. Rate control: Metoprolol 5 mg IV (cautious, given pulmonary edema)
5. Consider anticoagulation for new-onset AFib

Response at 30 minutes:

• SpO₂ improved to 94% on CPAP
• RR decreased to 24/min
• BP 150/90 mmHg
• Patient reports subjective improvement

Continue CPAP and medical therapy. Admit to ICU/telemetry unit.

Outcome: Patient improved over 6 hours, transitioned to nasal cannula, then room air by 24 hours.

Teaching Points:

• CPAP/BiPAP reduces intubation by ~50% in ACPE
• BNP > 500 pg/mL supports cardiac cause (vs ARDS)
• NIV provides immediate symptomatic relief while diuretics work
• Avoid morphine (no benefit, possible harm)

---

Case 4: Opioid Overdose (Type 2 RF from Hypoventilation)

Presentation: A 32-year-old man found unresponsive at home. Bystanders report possible drug use. GCS 6, pinpoint pupils, RR 6/min, shallow breathing, SpO₂ 82% on room air, BP 110/70 mmHg, HR 55 bpm.

Initial ABG (on room air):

• pH 7.18
• PaCO₂ 82 mmHg
• PaO₂ 54 mmHg
• HCO₃⁻ 26 mEq/L

Calculate A-a gradient:

• PAO₂ = 150 - (82/0.8) = 150 - 102.5 = 47.5 mmHg
• A-a gradient = 47.5 - 54 = -6.5 mmHg (essentially normal)

Interpretation: Acute Type 2 respiratory failure from hypoventilation (normal A-a gradient confirms extrapulmonary cause). Severe respiratory acidosis.

Management:

1. Naloxone 0.4 mg IV (may need repeat doses or infusion)
2. Bag-mask ventilation while awaiting naloxone effect
3. Supplemental oxygen 15 L non-rebreather

Response:

• After 2 doses naloxone (total 0.8 mg), patient awakens, RR improves to 16/min
• SpO₂ 98% on 15 L NRB
• GCS improves to 14

Repeat ABG (20 minutes later, on 15 L NRB):

• pH 7.32
• PaCO₂ 52 mmHg
• PaO₂ 248 mmHg

A-a gradient now: Minimal (on supplemental O₂)

Disposition: Admit for observation (risk of re-sedation as naloxone wears off, may need naloxone infusion)

Teaching Points:

• Normal A-a gradient distinguishes hypoventilation from pulmonary causes
• In pure hypoventilation, oxygenation responds well to supplemental O₂
• Naloxone short half-life (~30-60 min) vs fentanyl/methadone (long-acting opioids) → risk of re-sedation
• If no response to naloxone, consider intubation and alternative diagnoses

---

Case 5: Myasthenic Crisis

Presentation: A 55-year-old woman with myasthenia gravis presents with 2 days of worsening weakness, diplopia, and dysphagia. Now reporting dyspnea. She appears weak, speaks in short sentences, has bilateral ptosis and facial weakness. RR 28/min (shallow), SpO₂ 92% on room air.

ABG (on room air):

• pH 7.38
• PaCO₂ 44 mmHg
• PaO₂ 78 mmHg

Bedside Pulmonary Function:

• Vital capacity (VC): 12 mL/kg (normal > 70 mL/kg) - critically low
• Negative inspiratory force (NIF): -18 cm H₂O (normal < -30) - weak

Interpretation: Impending neuromuscular respiratory failure. ABG still "normal" but VC and NIF indicate imminent failure.

Key Teaching Point: In neuromuscular disease, do not wait for ABG to worsen - monitor VC and NIF. Intubate electively before crisis.

Indications for Intubation in Myasthenic Crisis:

• VC less than 15-20 mL/kg
• NIF >-20 to -30 cm H₂O (less negative = weaker)
• Declining trend in serial measurements
• Bulbar weakness with aspiration risk

Management:

1. Elective intubation (before respiratory arrest)
2. AVOID succinylcholine (prolonged paralysis in myasthenia)
3. Use rocuronium at reduced dose (increased sensitivity)
4. Plasmapheresis or IVIG to treat myasthenic crisis
5. Adjust anticholinesterase medications

Outcome: Patient intubated, underwent plasmapheresis, improved over 7 days, successfully extubated.

Teaching Points:

• Neuromuscular patients may not appear dyspneic despite severe respiratory compromise
• Serial VC and NIF measurements guide intubation
• Patients often do not "feel" short of breath (reduced respiratory drive)
• Weak cough → aspiration risk

---

Detailed ABG Interpretation Practice

Example 1: Mixed Respiratory and Metabolic Acidosis

ABG:

• pH 7.18
• PaCO₂ 68 mmHg
• PaO₂ 55 mmHg
• HCO₃⁻ 24 mEq/L
• Lactate 6.2 mmol/L

Step-by-step interpretation:

1. pH 7.18 = severe acidemia
2. PaCO₂ 68 = elevated (respiratory acidosis contribution)
3. HCO₃⁻ 24 = normal (no metabolic compensation yet)
4. Expected compensation: For acute respiratory acidosis, HCO₃⁻ should increase by 1 for every 10 mmHg rise in PaCO₂
   • PaCO₂ rose from 40 to 68 = +28 mmHg
   • Expected HCO₃⁻: 24 + 2.8 ≈ 27 mEq/L
   • Actual HCO₃⁻: 24 (lower than expected)
5. Conclusion: Mixed respiratory acidosis + metabolic acidosis (lactic acidosis)

Clinical Scenario: Severe pneumonia with septic shock - both respiratory failure (↑PaCO₂) and tissue hypoperfusion (↑lactate causing metabolic acidosis)

---

Example 2: Respiratory Alkalosis with Hypoxemia

ABG (on room air):

• pH 7.52
• PaCO₂ 28 mmHg
• PaO₂ 58 mmHg
• HCO₃⁻ 23 mEq/L

A-a gradient: PAO₂ = 150 - 35 = 115; A-a = 115 - 58 = 57 mmHg (markedly elevated)

Interpretation:

• Type 1 respiratory failure (hypoxemia, elevated A-a gradient)
• Respiratory alkalosis (compensatory hyperventilation from hypoxemia)
• Pulmonary cause (elevated A-a gradient)

Differential: Pneumonia, PE, early ARDS, interstitial lung disease

Clinical Pearl: Patients with acute hypoxemia often hyperventilate, causing low PaCO₂ and alkalosis. This is a compensatory mechanism.

---

Example 3: Acute vs Chronic Hypercapnia

Patient A - Acute Type 2 RF:

• pH 7.24
• PaCO₂ 62 mmHg
• HCO₃⁻ 26 mEq/L

Patient B - Chronic Type 2 RF (compensated):

• pH 7.38
• PaCO₂ 62 mmHg
• HCO₃⁻ 36 mEq/L

Comparison:

• Same PaCO₂ (62 mmHg) but vastly different pH
• Patient A: Acute (pH less than 7.35, normal HCO₃⁻) - requires intervention (BiPAP vs intubation)
• Patient B: Chronic compensated (pH normal, elevated HCO₃⁻) - this may be baseline, needs less urgent intervention

Clinical Implication: Do not panic over "high" PaCO₂ if pH is compensated. Know the patient's baseline.

---

Example 4: Calculate Ideal Tidal Volume for ARDS

Patient: 180 cm tall male, actual weight 95 kg

Step 1 - Calculate IBW:

• Male IBW = 50 + 2.3 × (inches over 5 feet)
• Height = 180 cm = 70.9 inches = 5 feet 10.9 inches
• IBW = 50 + 2.3 × 10.9 = 75 kg

Step 2 - Calculate target Vt:

• Lung-protective: 6 mL/kg IBW
• Vt = 6 × 75 = 450 mL

Common Error: Using actual weight (95 kg) would give Vt = 570 mL (too high, risk of volutrauma!)

Ventilator Settings:

• Vt: 450 mL
• Rate: 16-20/min
• PEEP: 10-12 cm H₂O (ARDS)
• FiO₂: Titrate to SpO₂ 88-95%

Monitor:

• Plateau pressure less than 30 cm H₂O
• Driving pressure less than 15 cm H₂O

---

Ventilator Troubleshooting

High Peak Airway Pressure Alarm

Differential Diagnosis:

Key: Check plateau pressure (end-inspiratory hold)

• Normal plateau, high peak: Airway obstruction (ETT, mucus, bronchospasm)
• High plateau: Lung pathology or chest wall restriction

---

Low Tidal Volume Alarm

Causes:

1. Circuit disconnection - Check connections
2. ETT cuff leak - Check cuff pressure (should be 20-30 cm H₂O)
3. Pneumothorax - Decreased compliance, CXR
4. Patient breathing over ventilator - Tachypnea, inadequate sedation

Management:

• Inspect circuit and connections
• Measure cuff pressure
• Assess patient (pain, anxiety, sedation)
• Consider CXR if pneumothorax suspected

---

High Minute Ventilation Alarm

Causes:

• Tachypnea (pain, anxiety, fever, hypoxemia, metabolic acidosis)
• Sepsis (increased metabolic demand)
• Inadequate sedation

Management:

1. Assess patient: Vitals, ABG, lactate
2. Treat pain/anxiety
3. Treat underlying cause (sepsis, metabolic acidosis)
4. Consider adjusting ventilator settings (pressure support, sedation)

---

Auto-PEEP (Intrinsic PEEP)

Definition: Incomplete exhalation before next breath → air trapping

Common in: COPD, asthma, high minute ventilation

Detection:

• End-expiratory pause maneuver (PEEP continues to rise after exhalation)
• Flow-time waveform: Expiratory flow doesn't return to zero before next breath

Consequences:

• ↑ Work of breathing
• Hypotension (↑ intrathoracic pressure → ↓ venous return)
• Barotrauma

Management:

1. Reduce respiratory rate (longer expiratory time)
2. Reduce tidal volume (less air to exhale)
3. Increase inspiratory flow (shortens inspiratory time, prolongs expiratory time)
4. Bronchodilators (if bronchospasm)
5. Consider adding external PEEP (controversial, may help trigger breaths)
6. Sedate (reduce patient's intrinsic rate)

---

Patient-Ventilator Dyssynchrony

Types:

General approach:

1. Sedate if agitated
2. Review ventilator waveforms (pressure, flow, volume)
3. Adjust trigger, flow, and cycling parameters
4. Consider switching modes (volume vs pressure control)
5. If refractory, deepen sedation or consider paralysis

---

Advanced Management Strategies

ARDSNet PEEP/FiO₂ Tables

Lower PEEP/Higher FiO₂ Strategy (typically used initially):

Higher PEEP/Lower FiO₂ Strategy (for moderate-severe ARDS):

How to use:

1. Start with lower PEEP table
2. Titrate FiO₂ and PEEP together to achieve SpO₂ 88-95%
3. For moderate/severe ARDS (P/F less than 200), consider higher PEEP table
4. Always keep plateau pressure less than 30 cm H₂O

---

Prone Positioning Protocol

Indications:

• ARDS with P/F ratio less than 150
• Within 36 hours of ARDS onset
• FiO₂ ≥0.6 and PEEP ≥5 cm H₂O

Contraindications (relative):

• Spinal instability
• Open chest/abdomen
• Pregnancy
• Increased intracranial pressure
• Recent tracheostomy (less than 48 hours)
• Severe hemodynamic instability

Procedure (requires 5 people):

1. Pre-oxygenate (FiO₂ 1.0)
2. Ensure adequate sedation ± paralysis
3. Protect eyes (tape shut, padding)
4. Position arms (swimmer's position)
5. Turn patient prone (synchronized team effort)
6. Position head to side, rotate every 2-4 hours
7. Pressure point care (face, chest, pelvis, knees)

Duration: 16 hours prone, then 8 hours supine

Expected response: P/F ratio improvement within first 1-2 hours

Complications:

• Pressure ulcers (face, anterior chest)
• ETT dislodgement
• Line/tube dislodgement
• Corneal abrasion
• Transient desaturation during turning

---

Neuromuscular Blockade in ARDS

Evidence: ACURASYS trial (2010) showed improved oxygenation and possibly reduced mortality in early severe ARDS. [18]

Indications:

• Severe ARDS (P/F less than 150)
• Patient-ventilator dyssynchrony despite sedation
• Plateau pressure persistently > 30 cm H₂O

Protocol:

• Cisatracurium 15 mg bolus, then 37.5 mg/hour infusion
• Duration: 48 hours (no benefit to longer)
• Deep sedation required (RASS -5)
• Daily interruption not recommended during paralysis

Monitoring:

• Train-of-four (TOF) monitoring
• Adequate sedation
• DVT prophylaxis
• Eye care

Risks:

• ICU-acquired weakness
• Prolonged ventilation
• Awareness (ensure adequate sedation)

---

Extracorporeal Membrane Oxygenation (ECMO)

Indications (consider for refractory hypoxemia):

• P/F ratio less than 80 for > 6 hours OR
• P/F ratio less than 50 for > 3 hours
• pH less than 7.25 with PaCO₂ > 60 mmHg for > 6 hours
• Despite maximal conventional therapy (lung-protective vent, prone, NMB, optimized PEEP)

EOLIA Trial (2018): [20]

• ECMO for severe ARDS did not show significant mortality benefit
• High crossover rate (28% of control group received ECMO)
• May have mortality benefit in most severe cases

Contraindications:

• Irreversible underlying condition
• Multi-organ failure
• Advanced age with poor functional status
• Prolonged high FiO₂/high pressure (lung damage irreversible)

ECMO Centers: Transfer to experienced center if considering ECMO

---

Patient Education and Communication

Explaining Respiratory Failure to Patients/Families

Simple Explanation: "Your lungs are having trouble doing their job of getting oxygen into your blood and removing carbon dioxide. This can be from an infection, fluid in the lungs, or other problems. We are helping your lungs by giving extra oxygen (or using a breathing machine) while we treat the underlying cause."

When NIV is Needed: "We're going to use a mask that gently pushes air into your lungs to help you breathe more easily. This may prevent the need for a breathing tube. It's important to keep the mask on and try to relax and breathe with the machine."

When Intubation is Needed: "Your lungs need more support than we can provide with a mask. We need to place a breathing tube and use a ventilator (breathing machine) to help your lungs rest and heal. You will be sedated and comfortable. The tube will come out once your lungs improve."

End-of-Life Discussions

For patients with severe respiratory failure and poor prognosis:

Framework:

1. Assess patient/family understanding: "What have the doctors told you so far?"
2. Provide information: Explain severity, prognosis, treatment options
3. Explore goals: "What's most important to you?" "What are you hoping for?"
4. Discuss options:
   • Full intensive care (intubation, pressors, ICU)
   • Trial of NIV with re-evaluation
   • Comfort measures only
5. Make recommendation: Based on medical assessment and patient values
6. Support decision: Reassure comfort will be maintained

Comfort-focused NIV:

• NIV can be used palliatively for dyspnea relief
• Does not require ICU
• Can stop when patient wishes
• Focus on comfort, not ABG numbers

---

Quality Improvement and Metrics

Hospital Performance Measures

Audit and Feedback

Areas for review:

1. Appropriate use of NIV (vs intubation)
2. Ventilator settings in ARDS (tidal volume, plateau pressure)
3. Time to extubation readiness assessment
4. Reintubation rates
5. Mortality by respiratory failure type

---

Common Pitfalls and How to Avoid Them

Pitfall 1: Over-Oxygenating COPD Patients

Error: Targeting SpO₂ 94-98% in COPD patient

Consequence: Worsening hypercapnia, CO₂ narcosis

Solution: Target SpO₂ 88-92% in known/suspected COPD or chronic Type 2 RF [11]

---

Pitfall 2: Using Actual Body Weight for Tidal Volume

Error: 100 kg patient, Vt set at 600 mL (6 mL/kg actual weight)

Consequence: Volutrauma, increased mortality in ARDS

Solution: Always calculate ideal body weight and use 6 mL/kg IBW for ARDS

---

Pitfall 3: Ignoring Plateau Pressure

Error: Focusing only on peak pressures

Consequence: Missing elevated plateau pressure → barotrauma

Solution: Check plateau pressure (end-inspiratory hold) every shift, keep less than 30 cm H₂O

---

Pitfall 4: Delayed Intubation in NIV Failure

Error: Continuing NIV for > 2-4 hours despite worsening acidosis, work of breathing

Consequence: Respiratory arrest, difficult intubation in fatigued/hypoxemic patient

Solution: Re-assess ABG at 1-2 hours. If pH less than 7.25 or clinical deterioration, intubate early.

---

Pitfall 5: Not Recognizing Neuromuscular Respiratory Failure

Error: Waiting for severe hypoxemia/hypercapnia in myasthenia gravis patient

Consequence: Urgent/emergent intubation in suboptimal conditions

Solution: Monitor vital capacity and NIF. Intubate electively if VC less than 20 mL/kg or NIF >-20.

---

Pitfall 6: Excessive Sedation Post-Intubation

Error: Deep sedation for days without interruption or SBT assessment

Consequence: Prolonged ventilation, delirium, ICU weakness

Solution: Daily sedation interruption, daily SBT assessment for extubation readiness

---

Pitfall 7: Using NIV in Severe Asthma

Error: Applying BiPAP to patient with severe asthma exacerbation

Consequence: Risk of pneumothorax, pneumomediastinum (barotrauma)

Solution: In severe asthma with impending failure, intubate (avoid NIV). Use low PEEP, low rate post-intubation.

---

Exam Preparation: Viva Scenarios

Viva Scenario 1: "How would you manage this patient with ARDS?"

Opening Statement: "ARDS is defined by the Berlin criteria as acute onset bilateral infiltrates within one week of a known insult, with respiratory failure not fully explained by cardiac failure, and a P/F ratio less than 300 with PEEP of at least 5. Mortality ranges from 27% for mild ARDS to 45% for severe ARDS with P/F ratio less than 100."

Approach:

1. Confirm diagnosis: Berlin criteria, identify precipitant (sepsis, pneumonia, aspiration)
2. Initial management:
   • Oxygen therapy escalation
   • Treat underlying cause (antibiotics, source control)
   • Consider NIV trial if mild (P/F 200-300)
3. Intubation criteria: Refractory hypoxemia, severe work of breathing, P/F less than 150-200
4. Ventilator management:
   • Lung-protective: 6 mL/kg IBW, plateau less than 30, driving pressure less than 15
   • PEEP per ARDSNet table
   • Permissive hypercapnia (pH ≥7.20)
5. Adjunctive therapies for severe ARDS (P/F less than 150):
   • Prone positioning 16 hours/day (50% mortality reduction)
   • Conservative fluid strategy
   • Consider neuromuscular blockade for 48 hours
   • ECMO for refractory hypoxemia (P/F less than 80)

Key Evidence to Cite:

• "The ARDSNet trial in 2000 showed low tidal volume ventilation reduced mortality by 9% absolute."
• "The PROSEVA trial in 2013 demonstrated prone positioning reduced mortality from 33% to 16% in severe ARDS."
• "Berlin criteria replaced the older Murray score in 2012 and better predict mortality."

---

Viva Scenario 2: "This COPD patient has pH 7.26 and CO₂ of 65. What do you do?"

Opening Statement: "This patient has acute-on-chronic Type 2 respiratory failure with respiratory acidosis. The pH of 7.26 indicates acute decompensation requiring intervention."

Structured Answer:

1. Immediate assessment:

   • Airway, breathing, circulation
   • Assess work of breathing, mental status
   • Controlled oxygen (target SpO₂ 88-92%)

2. First-line intervention - BiPAP:

   • Strong evidence: NNT 4-5 to prevent intubation
   • Settings: IPAP 10-12, EPAP 4-5, FiO₂ to target
   • Reduces intubation by 65%, mortality by 55%

3. Medical therapy:

   • Nebulized bronchodilators (albuterol + ipratropium)
   • Systemic corticosteroids (prednisone 40 mg × 5 days)
   • Antibiotics if increased sputum purulence

4. Re-assessment at 1-2 hours:

   • Repeat ABG
   • If pH improves to > 7.30, continue BiPAP
   • If pH less than 7.25 or deterioration, intubate

5. Intubation criteria:

   • pH less than 7.20-7.25 despite BiPAP
   • Altered mental status
   • Hemodynamic instability
   • Respiratory fatigue

Follow-up Question: "What if the patient refuses intubation?" "I would have a goals-of-care discussion to understand their values and preferences. Options include continuing NIV as comfort measure, transitioning to comfort care if NIV fails, or proceeding with intubation if they change their mind. I would ensure the patient understands the likely outcomes of each option."

---

Viva Scenario 3: "Tell me about the A-a gradient."

Definition: "The alveolar-arterial oxygen gradient measures the difference between alveolar oxygen (calculated) and arterial oxygen (measured from ABG). It helps distinguish pulmonary from extrapulmonary causes of hypoxemia."

Calculation: "PAO₂ is calculated using the alveolar gas equation: PAO₂ equals FiO₂ times atmospheric pressure minus water vapor pressure, minus PaCO₂ divided by the respiratory quotient, typically 0.8. At sea level on room air, this simplifies to approximately 150 minus PaCO₂ divided by 0.8. The A-a gradient is then PAO₂ minus PaO₂."

Normal Values: "The normal A-a gradient is 5 to 15 mmHg in young adults, increasing with age. A rough estimate is age divided by 4 plus 4."

Clinical Application: "A normal A-a gradient with hypoxemia indicates an extrapulmonary cause such as hypoventilation from opioid overdose, neuromuscular weakness, or low inspired oxygen. An elevated A-a gradient indicates a pulmonary cause such as V/Q mismatch in pneumonia, shunt in ARDS, or diffusion defect in pulmonary fibrosis."

---

Summary: Key Points for Exam Success

Must-Know Classifications

1. Type 1 (Hypoxemic): PaO₂ less than 60, normal/low PaCO₂, elevated A-a gradient
2. Type 2 (Hypercapnic): PaCO₂ > 50, ± hypoxemia, acute if pH less than 7.35
3. ARDS Berlin: Bilateral infiltrates, P/F less than 300, within 1 week of insult, not cardiac
4. ARDS Severity: Mild 200-300 (27%), Moderate 100-200 (32%), Severe less than 100 (45%)

Must-Know Evidence

1. ARDSNet (2000): Low Vt (6 mL/kg IBW) reduces mortality 9% [16]
2. PROSEVA (2013): Prone positioning reduces mortality 50% (P/F less than 150) [17]
3. NIV for COPD (2017): NNT 4-5, reduces intubation 65%, mortality 55% [6]
4. NIV for ACPE (2010): Reduces intubation ~50% [7]
5. RENOVATE (2025): HFNC noninferior to NIV in most ARF types [10]
6. FACTT (2006): Conservative fluids reduce ventilator days in ARDS [19]

Must-Know Calculations

1. A-a gradient: PAO₂ - PaO₂ (normal less than 15, increases with age)
2. P/F ratio: PaO₂ / FiO₂ (normal > 400, ARDS less than 300)
3. Ideal body weight: Male = 50 + 2.3 × (inches > 5 feet); Female = 45.5 + 2.3 × (inches > 5 feet)
4. Target Vt in ARDS: 6 mL/kg IBW (NOT actual weight!)

Must-Know Management

1. COPD: SpO₂ 88-92%, BiPAP first-line, steroids × 5 days
2. ARDS: Low Vt, plateau less than 30, prone if P/F less than 150
3. ACPE: CPAP/BiPAP, diuretics, vasodilators
4. NIV failure: Re-assess 1-2 hours, intubate if pH less than 7.25 or deterioration

Common Mistakes That Fail Exams

1. Using actual weight instead of IBW for tidal volume
2. Not knowing Berlin criteria for ARDS
3. Targeting SpO₂ > 94% in COPD
4. Not knowing ARDSNet trial (low tidal volume)
5. Not knowing PROSEVA trial (prone positioning)
6. Confusing acute vs chronic hypercapnia (check pH and HCO₃⁻)